Literature DB >> 22269621

Statin use and musculoskeletal pain among adults with and without arthritis.

Catherine Buettner1, Matthew J Rippberger, Julie K Smith, Suzanne G Leveille, Roger B Davis, Murray A Mittleman.   

Abstract

BACKGROUND: Musculoskeletal symptoms are common adverse effects of statins, yet little is known about the prevalence of musculoskeletal pain and statin use in the general population.
METHODS: We conducted a cross-sectional study of the National Health and Nutrition Examination Survey 1999-2004. We estimated the prevalence of self-reported musculoskeletal pain according to statin use and calculated prevalence ratio estimates of musculoskeletal pain obtained from adjusted multiple logistic regression modeling.
RESULTS: Among 5170 participants without arthritis, the unadjusted prevalence of musculoskeletal pain was significantly higher for statin users reporting pain in any region (23% among statin users, 95% confidence interval [CI], 19-27, compared with 18% among those not using statins, 95% CI, 17-20; P=.02) and in the lower extremities (12% among statin users, 95% CI, 8-16, compared with 8% among those not using statins, 95% CI, 7-9; P=.02). Conversely, among 3058 participants with arthritis, statin use was not associated with higher musculoskeletal pain in any region. After controlling for confounders, among those without arthritis, statin use was associated with a significantly higher prevalence of musculoskeletal pain in any region, the lower back, and the lower extremities (adjusted prevalence ratios: 1.33 [CI, 1.06-1.67]; 1.47 [CI, 1.02-2.13]; 1.59 [CI, 1.12-2.22], respectively). Among participants with arthritis, no association was observed between musculoskeletal pain and statin use on adjusted analyses.
CONCLUSION: In this population-based study, statin use was associated with a higher prevalence of musculoskeletal pain, particularly in the lower extremities, among individuals without arthritis. Evidence that statin use was associated with musculoskeletal pain among those with arthritis was lacking.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22269621      PMCID: PMC3266514          DOI: 10.1016/j.amjmed.2011.08.007

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

Review 1.  Musculoskeletal pain associated with corticosteroid therapy in cancer.

Authors:  Deborah A Frieze
Journal:  Curr Pain Headache Rep       Date:  2010-08

2.  Validation of a surveillance case definition for arthritis.

Authors:  Jeffrey J Sacks; Leslie R Harrold; Charles G Helmick; Jerry H Gurwitz; Srinivas Emani; Robert A Yood
Journal:  J Rheumatol       Date:  2005-02       Impact factor: 4.666

3.  Best-selling human medicines 2002-2004.

Authors:  Krishan Maggon
Journal:  Drug Discov Today       Date:  2005-06-01       Impact factor: 7.851

4.  Outcomes in 45 patients with statin-associated myopathy.

Authors:  Karen E Hansen; Julie P Hildebrand; Edwin E Ferguson; James H Stein
Journal:  Arch Intern Med       Date:  2005 Dec 12-26

Review 5.  Statin-associated myopathy.

Authors:  Paul D Thompson; Priscilla Clarkson; Richard H Karas
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

6.  Colchicine myopathy and neuropathy.

Authors:  R W Kuncl; G Duncan; D Watson; K Alderson; M A Rogawski; M Peper
Journal:  N Engl J Med       Date:  1987-06-18       Impact factor: 91.245

7.  Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.

Authors:  Eric Bruckert; Gilles Hayem; Sylvie Dejager; Caroline Yau; Bernard Bégaud
Journal:  Cardiovasc Drugs Ther       Date:  2005-12       Impact factor: 3.727

8.  Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes.

Authors:  Bernard M Y Cheung; Ian J Lauder; Chu-Pak Lau; Cyrus R Kumana
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

9.  A comprehensive description of muscle symptoms associated with lipid-lowering drugs.

Authors:  Sylvia Franc; Sylvie Dejager; Eric Bruckert; Marina Chauvenet; Philippe Giral; Gérard Turpin
Journal:  Cardiovasc Drugs Ther       Date:  2003 Sep-Nov       Impact factor: 3.727

10.  Accuracy of Medicare claims data for rheumatologic diagnoses in total hip replacement recipients.

Authors:  Elena Losina; Jane Barrett; John A Baron; Jeffrey N Katz
Journal:  J Clin Epidemiol       Date:  2003-06       Impact factor: 6.437

View more
  33 in total

Review 1.  Primary prevention: do the very elderly require a different approach?

Authors:  Janice B Schwartz
Journal:  Trends Cardiovasc Med       Date:  2014-10-18       Impact factor: 6.677

2.  A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints.

Authors:  Aldo Moreno-Ulloa; Nayelli Nájera-García; Marcela Hernández; Israel Ramírez-Sánchez; Pam R Taub; Yongxuan Su; Ernesto Beltrán-Partida; Guillermo Ceballos; Sundeep Dugar; George Schreiner; Brookie M Best; Theodore P Ciaraldi; Robert R Henry; Francisco Villarreal
Journal:  Food Funct       Date:  2018-01-24       Impact factor: 5.396

Review 3.  Statins: pros and cons.

Authors:  Iago Pinal-Fernandez; Maria Casal-Dominguez; Andrew L Mammen
Journal:  Med Clin (Barc)       Date:  2017-12-29       Impact factor: 1.725

4.  The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Authors:  R A Wilke; L B Ramsey; S G Johnson; W D Maxwell; H L McLeod; D Voora; R M Krauss; D M Roden; Q Feng; R M Cooper-Dehoff; L Gong; T E Klein; M Wadelius; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2012-05-23       Impact factor: 6.875

5.  Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study.

Authors:  Travis Y Morioka; Alice J Lee; Suzanne Bertisch; Catherine Buettner
Journal:  Atherosclerosis       Date:  2014-11-20       Impact factor: 5.162

Review 6.  Precision Cardiovascular Medicine: State of Genetic Testing.

Authors:  John R Giudicessi; Iftikhar J Kullo; Michael J Ackerman
Journal:  Mayo Clin Proc       Date:  2017-04       Impact factor: 7.616

Review 7.  Treatment Options for Statin-Associated Muscle Symptoms.

Authors:  Ulrich Laufs; Hubert Scharnagl; Martin Halle; Eberhard Windler; Matthias Endres; Winfried März
Journal:  Dtsch Arztebl Int       Date:  2015-10-30       Impact factor: 5.594

8.  Effects of Coenzyme Q10 on Skeletal Muscle Oxidative Metabolism in Statin Users Assessed Using 31P Magnetic Resonance Spectroscopy: a Randomized Controlled Study.

Authors:  Catherine Buettner; Robert L Greenman; Long H Ngo; Jim S Wu
Journal:  J Nat Sci       Date:  2016

9.  Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial.

Authors:  Catherine Buettner; Rony-Reuven Nir; Suzanne M Bertisch; Carolyn Bernstein; Aaron Schain; Murray A Mittleman; Rami Burstein
Journal:  Ann Neurol       Date:  2015-11-13       Impact factor: 10.422

10.  The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Authors:  L B Ramsey; S G Johnson; K E Caudle; C E Haidar; D Voora; R A Wilke; W D Maxwell; H L McLeod; R M Krauss; D M Roden; Q Feng; R M Cooper-DeHoff; L Gong; T E Klein; M Wadelius; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2014-06-11       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.